John E. Scott, Ph.D.
Associate Professor of Pharmaceutical Sciences
Approximately 15-20% of breast cancers have a triple negative phenotype (negative for ER and PR expression and lack ErbB2 overexpression) that correlates with aggressive cancer and limited treatment options. The focus of current research is the identification and characterization of cell signaling pathways and kinases in triple negative breast cancer that are critical for tumor growth and metastasis.
This research is focused on developing novel chemical biology approaches to the discovery of small organic molecules as research tools and potential drug leads. We develop and validate novel biochemical and cell-based assays and use them for high throughput screening of chemical libraries to identify biologically active compounds.
PON1 is a serum enzyme that appears to protect against atherosclerosis (i.e. hardening of the arteries) and the expression of PON1 varies considerably among individuals. The goal of this research is to better understand the regulation of PON1 expression and enzymatic activity. We are interested in novel activators of PON1 that may have therapeutic utility in atherosclerosis.